Aurinia Pharmaceuticals (NASDAQ:AUPH) Share Price Crosses Below 50 Day Moving Average – Here’s Why

Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPHGet Free Report) (TSE:AUP) crossed below its 50-day moving average during trading on Monday . The stock has a 50-day moving average of $12.05 and traded as low as $11.39. Aurinia Pharmaceuticals shares last traded at $11.84, with a volume of 1,091,293 shares.

Analysts Set New Price Targets

A number of brokerages recently issued reports on AUPH. HC Wainwright reiterated a “buy” rating and issued a $17.00 price objective on shares of Aurinia Pharmaceuticals in a report on Wednesday, July 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Aurinia Pharmaceuticals in a report on Wednesday, October 8th. Finally, Royal Bank Of Canada raised their price objective on shares of Aurinia Pharmaceuticals from $8.00 to $9.00 and gave the company an “outperform” rating in a report on Friday, August 1st. Two investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $13.00.

Get Our Latest Stock Analysis on Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Trading Up 2.5%

The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.63 and a current ratio of 5.23. The firm’s fifty day simple moving average is $12.05 and its 200-day simple moving average is $9.67. The stock has a market cap of $1.56 billion, a P/E ratio of 27.54 and a beta of 1.25.

Aurinia Pharmaceuticals (NASDAQ:AUPHGet Free Report) (TSE:AUP) last released its quarterly earnings results on Thursday, July 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.17 by ($0.01). Aurinia Pharmaceuticals had a return on equity of 20.06% and a net margin of 23.31%.The firm had revenue of $70.01 million for the quarter, compared to the consensus estimate of $64.27 million. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS. Equities research analysts expect that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current fiscal year.

Insider Activity at Aurinia Pharmaceuticals

In related news, Director Kevin Tang acquired 200,000 shares of Aurinia Pharmaceuticals stock in a transaction dated Tuesday, August 5th. The stock was bought at an average price of $11.68 per share, with a total value of $2,336,000.00. Following the transaction, the director directly owned 11,329,500 shares in the company, valued at $132,328,560. This represents a 1.80% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Over the last three months, insiders have purchased 1,300,000 shares of company stock worth $13,590,000. Company insiders own 12.20% of the company’s stock.

Institutional Trading of Aurinia Pharmaceuticals

Several large investors have recently modified their holdings of the stock. GAMMA Investing LLC grew its position in Aurinia Pharmaceuticals by 56.1% in the 1st quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company’s stock valued at $39,000 after purchasing an additional 1,744 shares during the period. MAI Capital Management bought a new stake in shares of Aurinia Pharmaceuticals during the 1st quarter worth $39,000. DekaBank Deutsche Girozentrale purchased a new stake in Aurinia Pharmaceuticals during the first quarter valued at about $60,000. USA Financial Formulas purchased a new stake in shares of Aurinia Pharmaceuticals in the third quarter worth about $107,000. Finally, Xponance Inc. purchased a new stake in shares of Aurinia Pharmaceuticals in the first quarter worth about $82,000. Institutional investors and hedge funds own 36.83% of the company’s stock.

Aurinia Pharmaceuticals Company Profile

(Get Free Report)

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.

Recommended Stories

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.